PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
23062767-12	2012	CONCLUSIONS: A high simvastatin dose or the combination of a low-dose simvastatin with ezetimibe reduce to a similar extent TLR2, TLR4 membrane expression and LPS-induced IL-6 and IL-1beta production in monocytes of hypercholesterolemic patients.	Ezetimibe	87-96	interleukin 6	Homo sapiens	171-175	
23013513-0	2013	Effects of simvastatin and ezetimibe on interleukin-6 and high-sensitivity C-reactive protein.	Ezetimibe	27-36	interleukin 6	Homo sapiens	40-53	
26687339-9	2016	RESULTS: The combination of ezetimibe plus rosuvastatin decreased total cholesterol, low-density lipoprotein cholesterol, hsCRP, IL-6, and MMP-9 levels at six and 12 months after treatment.	Ezetimibe	28-37	interleukin 6	Homo sapiens	129-133	
20185740-6	2010	Compared with weight loss alone, ezetimibe plus weight loss significantly (all P < 0.05) decreased IHTG content (-18%), plasma hs-CRP (-53%), interleukin-6 (-24%), LDL cholesterol (-18%), campesterol (-59%), and apoB-100 (-14%) levels, with a significant increase in plasma lathosterol concentrations (+43%).	Ezetimibe	33-42	interleukin 6	Homo sapiens	145-158	
20880729-8	2011	Ezetimibe was associated with a significant reduction in aortic wall MMP-9 (p = 0.02) and aortic wall IL-6 (p = 0.02), associated with a reduction in plasma lipids.	Ezetimibe	0-9	interleukin 6	Homo sapiens	102-106	
27818020-9	2017	Levels of soluble IL-6 in HUVEC supernatants were significantly lower after pre-incubation with ezetimibe.	Ezetimibe	96-105	interleukin 6	Homo sapiens	18-22